Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 5, 2012
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosisBarry G Arnason, Regina Berkovich, Anna Catania, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2025
Shaping the role of plasma exchange in autoimmune neurology: lessons learned from 67 years and over 90,000 proceduresBhupendra O Khatri, Regina Berkovich, Jay S Raval, et al.
The European Journal of Neuroscience|May 4, 2023
Meta-analysis of the effects of anti-migraine therapeutics in the rat trigeminovascular nociception model as a tool for design optimizationAntonina Dolgorukova, Ekaterina Protsenko, Julia Isaeva, et al.
Frontiers in Immunology|April 21, 2025
Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report seriesRegina Berkovich, Jonathan Calkwood, Heidi Crayton, et al.
Frontiers in Immunology|June 30, 2025
Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report seriesRegina Berkovich, Jonathan Calkwood, Heidi Crayton, et al.
Multiple Sclerosis and Related Disorders|August 13, 2024
Cross-prevalence of multiple sclerosis and stroke evaluated on cohorts of four independent specialty medical centersRegina Berkovich, Alexey Y Sokolov, Natalia A Totolyan, et al.
Therapeutic Advances in Neurological Disorders|April 29, 2017
Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trialRegina Berkovich, Rohit Bakshi, Lilyana Amezcua, et al.
Medicine|November 5, 2025
Effectiveness of teriflunomide in patients with relapsing multiple sclerosis who switched from other disease-modifying therapiesRegina Berkovich, Nupur Greene, Sheila R Reddy, et al.
Neurology and Therapy|October 23, 2024
COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record ReviewRahul H Dave, Heidi Crayton, Augusto Miravalle, et al.
Neurodegenerative Disease Management|October 26, 2022
Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapiesJohn Foley, Regina Berkovich, Mark Gudesblatt, et al.
Pageof 3